(Kidney Cancer) Opdivo + Cabometyx Combination Therapy Approved in Japan
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On August 25, 2021, Ono Pharmaceutical and Takeda Pharmaceutical announced that Opdivo (nivolumab) plus Cabometyx (cabozantinib) combination therapy received approval for treating patients with unresectable or metastatic renal cell carcinoma.
Kidney cancer affects approximately 25,000 new patients per year in Japan, with approximately 8,550 deaths annually. Renal cell carcinoma accounts for 90% of these cases.
This approval was based on the CheckMate-9ER Phase III clinical trial results. The trial assigned patients in a 1:1 ratio to either the Opdivo combination therapy group (every 2 weeks: Opdivo 240mg + once-daily Cabometyx 40mg) or the Sunitinib group (every 6 weeks: Sunitinib 50mg once daily for 4 weeks followed by 2 weeks rest). The primary endpoint was progression-free survival (PFS), and secondary endpoints were overall survival (OS) and objective response rate (ORR). Analysis results showed significant improvement in progression-free survival, overall survival, and objective response rate. The safety profile of the Opdivo plus Cabometyx combination therapy was consistent with previously reported adverse event data.
Source: https://www.ono.co.jp/news/20210825.html
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4